Akesion - One Solution

Of patients who undergo abdominal surgery, over 50% develop adverse adhesions between organs. Adhesions often lead to pain, infertility and, in severe cases, to life-threatening bowel obstruction. A new drug developed by the startup company Akesion removes the main precursor of these adhesions preventing the formation of adhesions as well as risky repeat surgeries that are stressful to patients.

LicenseDefault alugha License

More videos by this producer

archos CEO

2020 was particularly difficult because of the Covid 19 crisis, however, our team has shown tremendous resilience and in 2021 Archos intends to surprise with new innovations and an improved business model. We will invite our shareholders in early Q2 2021 for a presentation of our strategy plan.

Articles by this producer